ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
Transplantation and Cellular Therapy · 2024-12 · 30 (12) · 1139-1154
DOI: 10.1016/j.jtct.2024.09.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplantation and Cellular Therapy, 2024-12. Verfasst von Piyanuch Kongtim und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensi…. Hauptthemen laut MEDLINE: HLA Antigens, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft. The incidence of DSA varies across studies, depending on individual factors, detection or identification methods and thresholds considered clinically relevant. Although DSA testing by multiplex bead arrays remains semiquantitative, it has been widely adopted as a standard test in most transplant centers. Additional testing to determine risk of allograft rejection may include assays with HLA antigens in natural conformation, such as flow cytometric crossmatch, and/or antibody binding assays, such as C1q testing. Patients with low level of DSA ( 20,000 MFI) may be at very high-risk for engraftment failure despite current therapies. By contrast, in patients with moderate or high level of DSA, desensitization therapy can successfully mitigate DSA levels and improve donor cell engraftment rate, with comparable outcomes to patients without DSA. Treatment is largely empirical and multimodal, involving the removal, neutralization, and blocking of antibodies, as well as inhibition of antibody production to prevent activation of the complement cascade. Desensitization protocols are based on accumulated multicenter experience, while prospective multicenter studies remain lacking. Most patients require a full intensity protocol that includes plasma exchange, while protocols relying only on rituximab and intravenous immunoglobulin may be sufficient for patients with lower DSA levels and negative C1q and/or flow cytometric crossmatch. Monitoring DSA levels before and after HSCT could guide preemptive treatment when high levels persist after stem cell infusion. This paper aims to standardize current evidence-based practice and formulate future directions to improve upon current knowledge and advance treatment for this relatively rare, but potentially serious complication in allogeneic HSCT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Adult BMT Service, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
- Section of Bone Marrow Transplant and Cell Therapy, Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AK, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Kongtim, P., Vittayawacharin, P., Zou, J., Srour, S., Shaffer, B., Shapiro, R. M., Varma, A., McGuirk, J., Dholaria, B. R., McCurdy, S. R., DeZern, A. E., Bejanyan, N., Bashey, A., Furst, S., Castagna, L., Mariotti, J., Ruggeri, A., Bailen, R., Teshima, T., …, & Ciurea, S. O. (2024). ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transplantation and Cellular Therapy, 30(12), 1139-1154. https://doi.org/10.1016/j.jtct.2024.09.005
Vancouver
Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, et al. ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transplantation and Cellular Therapy. 2024;30(12):1139-1154. doi:10.1016/j.jtct.2024.09.005
BibTeX
@article{Kongtim2024,
author = {Kongtim, Piyanuch and Vittayawacharin, Pongthep and Zou, Jun and Srour, Samer and Shaffer, Brian and Shapiro, Roman M and Varma, Ankur and McGuirk, Joseph and Dholaria, Bhagirathbhai R and McCurdy, Shannon R and DeZern, Amy E and Bejanyan, Nelli and Bashey, Asad and Furst, Sabine and Castagna, Luca and Mariotti, Jacopo and Ruggeri, Annalisa and Bailen, Rebeca and Teshima, Takanori and Xiao-Jun, Huang and Bonfim, Carmen and Aung, Fleur and Cao, Kai and Carpenter, Paul A and Hamadani, Mehdi and Askar, Medhat and Fernandez-Vina, Marcelo and Girnita, Alin and Ciurea, Stefan O},
title = {ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies},
journal = {Transplantation and Cellular Therapy},
year = {2024},
volume = {30},
number = {12},
pages = {1139--1154},
doi = {10.1016/j.jtct.2024.09.005}
}
EUVIMED